The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| APPLIED GENETIC TECHNOL CORP | COM | 03820J100 | 7,075 | 1,455,904 | SH | SOLE | 1,455,904 | 0 | 0 | ||
| CIDARA THERAPEUTICS INC | COM | 171757107 | 3,867 | 1,356,813 | SH | SOLE | 1,356,813 | 0 | 0 | ||
| EIGER BIOPHARMACEUTICALS INC | COM | 28249U105 | 6,226 | 764,918 | SH | SOLE | 764,918 | 0 | 0 | ||
| GLAUKOS CORP | COM | 377322102 | 32,008 | 646,364 | SH | SOLE | 646,364 | 0 | 0 | ||
| KALVISTA PHARMACEUTICALS INC | COM | 483497103 | 4,895 | 388,766 | SH | SOLE | 388,766 | 0 | 0 | ||
| OBALON THERAPEUTICS INC | COM | 67424L209 | 346 | 380,224 | SH | SOLE | 380,224 | 0 | 0 | ||
| XENON PHARMACEUTICALS INC | COM | 98420N105 | 92 | 8,293 | SH | SOLE | 8,293 | 0 | 0 | ||
| VENUS CONCEPT INC | COM | 92332W105 | 1,528 | 658,657 | SH | SOLE | 658,657 | 0 | 0 | ||
| NEURONETICS INC | COM | 64131A105 | 5,009 | 1,030,689 | SH | SOLE | 1,030,689 | 0 | 0 | ||
| DARE BIOSCIENCE INC | COM | 23666P101 | 50 | 50,368 | SH | SOLE | 50,368 | 0 | 0 | ||
| THE REALREAL | COM | 88339P101 | 55,769 | 3,854,080 | SH | SOLE | 3,854,080 | 0 | 0 | ||
| PMV PHARMACEUTICALS INC | COM | 69353Y103 | 229,682 | 6,469,911 | SH | SOLE | 6,469,911 | 0 | 0 | ||